All
Phase 3 Trial of Fablyn Plus Verzenio for Metastatic Breast Cancer Initiates Registration
March 20th 2023Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.
Developmental Pathways: A Key to Effective Treatments for Lymphoid Malignancies
March 18th 2023Personalized medicine means not only more powerful drugs for cancers, but also more precise mechanisms that target the specific consequence of mutations and other alterations that drive cancer cell growth, sparing normal cells.